PURPOSE: To develop and evaluate an expanded version of the Hammersmith Functional Motor Scale allowing for evaluation of ambulatory SMA patients. PROCEDURES: Thirty-eight patients with SMA type II or III were evaluated using the Gross Motor Function Measure and the Hammersmith Functional Motor Scale. Based on statistical and clinical criteria, we selected 13 Gross Motor Function Measure items to develop an expanded HFMS. The expanded Hammersmith Functional Motor Scale was validated by comparison with the Gross Motor Function Measure minus the 13 items (GMFM-75) and an assessment of clinical function. The reliability of the expanded Hammersmith Functional Motor Scale in 36 patients was established. FINDINGS: The expanded Hammersmith Functional Motor Scale was highly correlated with the GMFM-75 and the clinical function assessment (p=0.97, and p=0.90). The expanded Hammersmith Functional Motor Scale showed excellent test-retest reliability (International Coordinating Committee = 0.99). CONCLUSIONS: The expanded Hammersmith Functional Motor Scale allows assessment of high functioning SMA type II and III patients. Ease of administration and correlation with established motor function measures justify use in future SMA clinical trials.
PURPOSE: To develop and evaluate an expanded version of the Hammersmith Functional Motor Scale allowing for evaluation of ambulatory SMApatients. PROCEDURES: Thirty-eight patients with SMA type II or III were evaluated using the Gross Motor Function Measure and the Hammersmith Functional Motor Scale. Based on statistical and clinical criteria, we selected 13 Gross Motor Function Measure items to develop an expanded HFMS. The expanded Hammersmith Functional Motor Scale was validated by comparison with the Gross Motor Function Measure minus the 13 items (GMFM-75) and an assessment of clinical function. The reliability of the expanded Hammersmith Functional Motor Scale in 36 patients was established. FINDINGS: The expanded Hammersmith Functional Motor Scale was highly correlated with the GMFM-75 and the clinical function assessment (p=0.97, and p=0.90). The expanded Hammersmith Functional Motor Scale showed excellent test-retest reliability (International Coordinating Committee = 0.99). CONCLUSIONS: The expanded Hammersmith Functional Motor Scale allows assessment of high functioning SMA type II and III patients. Ease of administration and correlation with established motor function measures justify use in future SMA clinical trials.
Authors: Stefan J Cano; Anna Mayhew; Allan M Glanzman; Kristin J Krosschell; Kathryn J Swoboda; Marion Main; Birgit F Steffensen; Carole Bérard; Françoise Girardot; Christine A M Payan; Eugenio Mercuri; Elena Mazzone; Bakri Elsheikh; Julaine Florence; Linda S Hynan; Susan T Iannaccone; Leslie L Nelson; Shree Pandya; Michael Rose; Charles Scott; Reza Sadjadi; Mackensie A Yore; Cynthia Joyce; John T Kissel Journal: Muscle Nerve Date: 2013-07-26 Impact factor: 3.217
Authors: Claudia D Wurster; Petra Steinacker; René Günther; Jan C Koch; Paul Lingor; Zeljko Uzelac; Simon Witzel; Kurt Wollinsky; Benedikt Winter; Alma Osmanovic; Olivia Schreiber-Katz; Rami Al Shweiki; Albert C Ludolph; Susanne Petri; Andreas Hermann; Markus Otto Journal: J Neurol Date: 2019-09-24 Impact factor: 4.849
Authors: Santiago Zuluaga-Sanchez; Megan Teynor; Christopher Knight; Robin Thompson; Thomas Lundqvist; Mats Ekelund; Annabelle Forsmark; Adrian D Vickers; Andrew Lloyd Journal: Pharmacoeconomics Date: 2019-06 Impact factor: 4.981
Authors: J Montes; M P McDermott; W B Martens; S Dunaway; A M Glanzman; S Riley; J Quigley; M J Montgomery; D Sproule; R Tawil; W K Chung; B T Darras; D C De Vivo; P Kaufmann; R S Finkel Journal: Neurology Date: 2010-03-09 Impact factor: 9.910
Authors: Kristin J Krosschell; Jo Anne Maczulski; Charles Scott; Wendy King; Jill T Hartman; Laura E Case; Donata Viazzo-Trussell; Janine Wood; Carolyn A Roman; Eva Hecker; Marianne Meffert; Maude Léveillé; Krista Kienitz; Kathryn J Swoboda Journal: Pediatr Phys Ther Date: 2013 Impact factor: 3.049
Authors: Suzan M Hammond; Gareth Hazell; Fazel Shabanpoor; Amer F Saleh; Melissa Bowerman; James N Sleigh; Katharina E Meijboom; Haiyan Zhou; Francesco Muntoni; Kevin Talbot; Michael J Gait; Matthew J A Wood Journal: Proc Natl Acad Sci U S A Date: 2016-09-12 Impact factor: 11.205
Authors: Petra Kaufmann; Michael P McDermott; Basil T Darras; Richard S Finkel; Douglas M Sproule; Peter B Kang; Maryam Oskoui; Andrei Constantinescu; Clifton L Gooch; A Reghan Foley; Michele L Yang; Rabi Tawil; Wendy K Chung; William B Martens; Jacqueline Montes; Vanessa Battista; Jessica O'Hagen; Sally Dunaway; Jean Flickinger; Janet Quigley; Susan Riley; Allan M Glanzman; Maryjane Benton; Patricia A Ryan; Mark Punyanitya; Megan J Montgomery; Jonathan Marra; Benjamin Koo; Darryl C De Vivo Journal: Neurology Date: 2012-10-17 Impact factor: 9.910
Authors: S Piepers; L H van den Berg; F Brugman; H Scheffer; M Ruiterkamp-Versteeg; B G van Engelen; C G Faber; M de Visser; W-L van der Pol; J H J Wokke Journal: J Neurol Date: 2008-06-30 Impact factor: 4.849
Authors: Douglas M Sproule; Jacqueline Montes; Megan Montgomery; Vanessa Battista; Dorcas Koenigsberger; Wei Shen; Mark Punyanitya; Darryl C De Vivo; Petra Kaufmann Journal: Neuromuscul Disord Date: 2009-05-07 Impact factor: 4.296